



News

PREGLEM ANNOUNCES THE APPOINTMENT OF DR IAN OSTERLOH AS CONSULTING CHIEF MEDICAL OFFICER

Geneva, Switzerland – 25 November 2009: PregLem, the Swiss biopharmaceutical company specializing in women's reproductive medicine, is pleased to announce the appointment of Dr Ian Osterloh as consultant, acting Chief Medical Officer.

Dr Osterloh has over 20 years of successful leadership experience in the pharmaceutical industry. At Pfizer he held prominent roles in Clinical Drug Development and Regulatory Affairs. He played a key role in the development and registration of VIAGRA™ for erectile dysfunction (ED). On this project he designed the Clinical Development Strategy, headed the clinical studies, and led the team that negotiated the label with the FDA, resulting in the approval of VIAGRA™ by both the FDA and the EMEA. He has also been instrumental in the determining the global medical and marketing strategy for this drug, and acted as a medical spokesperson to increase public awareness of ED and the drug.

He has played a prominent role in the regulatory approval of three other blockbuster products (DIFLUCAN™, NORVASC™, and ZOLOFT™), and he also became the Pfizer Research Therapeutic Area (TA) Head for Pain, where he developed a new strategy and portfolio of projects for the Pain Therapeutic Area.

Dr Osterloh has a BSc in Chemistry and an MSc in Advanced Analytical Chemistry from the University of Bristol. He qualified in Medicine from the University of London (Guy's Hospital Medical School). After starting his career as a doctor at teaching hospitals and district general hospitals with the NHS, he became a member of the Royal College of Physicians (MRCP) in 1985. He has also acted as a Principal Investigator for several phase I studies.

Dr Ernest Loumaye, PregLem's CEO and founder, said: "We are very pleased to bring Dr Osterloh into our team. His strong experience in designing clinical studies and regulatory affairs will bring valuable contributions to the development of our *first-in-class* compounds for the treatment of women's reproductive health conditions with the priority of gaining the European Marketing Authorization for PGL4001."

"I am very happy to have the opportunity to work with PregLem at such an interesting time in the development of such important and innovative products," said Dr Osterloh, "PregLem



has a very dynamic management team with valuable experience in the development, registration, and marketing of pharmaceutical compounds within its field. I look forward to collaborating with them in this upcoming new therapy area, and to supporting the development and registration of their compounds.” Dr Osterloh will be supporting PregLem on a part-time basis.

End

For further information please contact:

Solveig Hole
CEO Office
PregLem SA
Tel: +41 (0)22 884 03 40
solveig.hole@preglem.com

Notes to Editors:

About PregLem

PregLem is a Swiss speciality biopharmaceutical company, dedicated to the development and commercialization of a new class of drugs for women’s reproductive health conditions.

PregLem has an experienced senior management team, with a proven track record in developing, registering and commercializing reproductive health products. The company is backed by a blue chip investor base.

PregLem in-licensed ulipristal acetate from HRA Pharma to develop it for the treatment of uterine myoma (fibroids) in doses of 5 and 10 mg. HRA recently obtained a positive CHMP recommendation for approval of ulipristal acetate in emergency contraception, a significant step towards de-risking the registration of PregLem’s PGL4001 (see March 2009 press releases on www.hra.com and www.preglem.com).